Syndax Pharmaceuticals Inc

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $1.2m $2.1m $1.5m $1.5m $1.5m $139.7m $0 $0 $23.7m $172.4m
Operating Expenses $45.0m $64.1m $77.4m $59.1m $72.9m $113.5m $151.8m $230.0m $363.4m $445.4m
Operating Income (Loss) ($43.8m) ($62.0m) ($75.9m) ($57.5m) ($71.4m) $26.2m ($151.8m) ($230.0m) ($339.7m) ($273.1m)
Additional Financial Items
Net Income (Loss) Attributable to Parent ($44.5m) ($60.8m) ($74.0m) ($56.0m) ($73.2m) $24.9m ($149.3m) ($209.4m) ($318.8m) ($285.4m)
Net Income (Loss) Available to Common Stockholders, Basic ($47.1m) ($60.8m) ($74.0m) ($56.0m) ($77.1m) $24.9m ($149.3m) ($209.4m) ($318.8m) ($285.4m)
Earnings Per Share, Basic ($1.84) ($1.87) $0.48 ($2.46) ($2.98) ($3.72) ($3.29)
Earnings Per Share, Diluted ($3.22) ($2.90) ($2.92) ($1.84) ($1.87) $0.46 ($2.46) ($2.98) ($3.72) ($3.29)
Weighted Average Number of Shares Outstanding, Basic 52.1m 60.8m 70.4m 85.6m 86.6m
Weighted Average Number of Shares Outstanding, Diluted 53.6m 60.8m 70.4m 85.6m 86.6m
Research and Development Expense $31.7m $48.2m $60.1m $43.0m $50.4m $88.2m $118.5m $163.0m $241.6m $258.8m
General and Administrative Expense $13.3m $15.9m $17.3m $16.1m $22.5m $25.2m $33.3m $66.9m $120.9m $179.7m
Selling, General and Administrative Expense $13.3m $15.9m $17.3m $16.1m $22.5m $25.2m $33.3m $66.9m $120.9m $179.7m
Other Nonoperating Income (Expense) $41k ($269k) ($27k) ($79k) ($219k) $202k ($316k) ($361k) ($247k) ($1.3m)
Interest Expense (non-operating) $4.9m $6k
Interest Expense $956k $1.4m $1.9m $1.6m $2.4m $1.9m $3.1m $208k $4.9m $6k
Operating Lease, Expense $447k $425k $413k $440k $743k $1.1m $900k
Income Tax Expense (Benefit) $0 $0 $0 $0 $0 $0 $433k
Interest Income (Expense), Nonoperating, Net $956k $1.4m $1.9m $1.6m $2.4m $1.9m $3.1m $208k $4.9m $6k